Summary: Creative Biolabs provides GLP-compliant in vivo test services for anti-CS1 CAR-T cell therapy in multiple myeloma. CS1 or SLAMF7, CD319 is a cell-surface glycoprotein, which is manifested as a robust marker in CD138-purified primary tumor cells from the majority of multiple myeloma (MM) patients.